BioSpace News Archive

Eagle Pharmaceuticals, Inc. will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL.

Ausper Biopharma Co., Ltd. and AusperBio Therapeutic, Inc. today announced the completion of the first cohort dosing in a Phase 1 clinical trial evaluating AHB–137 in adult healthy volunteers and chronic hepatitis B (CHB) patients in New Zealand.

Allorion Therapeutics (“Allorion”), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B financing round.

ALX Oncology Holdings Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided clinical development and operational highlights.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent clinical and corporate updates.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022.

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced the Company’s fourth quarter and full year 2022 financial results will be released after market close on Thursday, March 16, 2023.

Lineage Cell Therapeutics, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.